MTOR and cholangiocarcinoma: To assess which pathway may be more relevant as a potential target of therapy in CCA, we grouped compounds with different chemical structure that acted on the same molecular target and investigated if there was an enrichment in selected molecular pathways amongst the drugs that were significantly active across the cell lines (Figure 1D).17, 18 We observed enrichment for microtubule-associated compounds and mTOR inhibitors in all cell lines.